妊娠高血圧腎症治療薬の世界市場レポート 2025年

妊娠高血圧腎症治療薬の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.3％で21億2,000万米ドルに成長します。予測期間の成長は、個別化医療、非侵襲的診断ツール、標的療法、健康公平性への取り組みに起因しています。予測期間における主な動向には、予防戦略、患者中心のケア、継続的モニタリング、規制の重点化などがあります。

妊婦の糖尿病罹患率の増加が、今後の妊娠高血圧腎症治療薬市場の拡大を牽引すると予想されます。糖尿病は、血糖値の上昇を特徴とする慢性代謝疾患であり、妊娠高血圧腎症など妊娠に悪影響を及ぼす可能性があります。メトホルミンは妊娠高血圧腎症の治療に使用される薬で、妊娠高血圧腎症を発症するリスクのある妊婦に広く使用されています。2022年12月現在、米国の生物医学図書館および情報センターである国立医学図書館のデータによると、2022年の妊娠糖尿病（GDM）症例は合計20,865例で、6.56％の増加を示しています。このように、妊婦の糖尿病患者の急増が妊娠高血圧腎症治療薬市場の成長の原動力になると予想されます。

生活習慣病の増加は、妊娠高血圧腎症治療薬市場の拡大を刺激します。生活習慣病は非感染性疾患（NCD）としても知られ、主に不健康な生活習慣の選択や行動に起因する健康状態の一群を包含します。妊娠高血圧腎症治療薬は、妊娠高血圧腎症の危険因子である高血圧、肥満、糖尿病などの生活習慣病の治療に役立っています。例えば、スイスに本部を置く国連の専門機関である世界保健機関（WHO）が2022年9月に報告したところによると、世界の年間死亡者数4,100万人のうち、非感染性疾患（NCDs）または慢性疾患が74％を占めています。その内訳は、心血管疾患による死亡が1,790万人、がんによる死亡が930万人、慢性呼吸器疾患による死亡が410万人、糖尿病による死亡が200万人です。その結果、生活習慣病の急増が妊娠高血圧腎症治療薬市場の成長を促す要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の妊娠高血圧腎症治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の妊娠高血圧腎症治療薬市場：成長率分析
• 世界の妊娠高血圧腎症治療薬市場の実績：規模と成長、2019～2024年
• 世界の妊娠高血圧腎症治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の妊娠高血圧腎症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の妊娠高血圧腎症治療薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 軽度妊娠高血圧腎症
• 重症妊娠高血圧腎症
• 世界の妊娠高血圧腎症治療薬市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 高血圧を下げる薬
• コルチコステロイド
• 抗けいれん薬
• 世界の妊娠高血圧腎症治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• その他
• 世界の妊娠高血圧腎症治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の妊娠高血圧腎症治療薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 診断センター
• その他
• 世界の妊娠高血圧腎症治療薬市場：軽度妊娠高血圧腎症のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 血圧管理
• タンパク尿モニタリング
• ライフスタイルの変更
• 世界の妊娠高血圧腎症治療薬市場：重症妊娠高血圧腎症のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 降圧薬
• 硫酸マグネシウム療法
• 緊急分娩管理

第7章 地域別・国別分析

• 世界の妊娠高血圧腎症治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の妊娠高血圧腎症治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 妊娠高血圧腎症治療薬市場：競合情勢
• 妊娠高血圧腎症治療薬市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Celgene Corp
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline PLC
• Takeda Pharmaceuticals Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Siemens Healthcare GmbH
• Boehringer Ingelheim Group
• Viatris Inc.
• Baxter International Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 妊娠高血圧腎症治療薬市場2029：新たな機会を提供する国
• 妊娠高血圧腎症治療薬市場2029：新たな機会を提供するセグメント
• 妊娠高血圧腎症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Preeclampsia drugs are medications used to manage and treat preeclampsia, a serious pregnancy complication characterized by high blood pressure and organ damage, particularly in the liver and kidneys. Healthcare professionals typically prescribe these drugs to pregnant women diagnosed with preeclampsia to help reduce blood pressure and prevent further complications.

The main types of preeclampsia drugs are categorized into treatments for mild preeclampsia and severe preeclampsia. Mild preeclampsia is a medical disorder that can affect pregnant women, often appearing after the 20th week of pregnancy. Treatment options for preeclampsia include medications to lower blood pressure, corticosteroids, and anticonvulsant medication. These drugs can be administered through various routes, including the oral route and parenteral (injectable) route. They are available through different distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Preeclampsia drugs are utilized by various end-users, including hospitals, specialty clinics, diagnostic centers, and other relevant healthcare facilities.

The preeclampsia drug market research report is one of a series of new reports from The Business Research Company that provides preeclampsia drug market statistics, including preeclampsia drug industry global market size, regional shares, competitors with a preeclampsia drug market share, detailed preeclampsia drug market segments, market trends and opportunities and any further data you may need to thrive in the preeclampsia drug industry. This preeclampsia drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.25 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increased maternal health awareness, research and development, neonatal health concerns, early detection.

The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to personalized medicine, non-invasive diagnostic tools, targeted therapies, health equity initiatives. Major trends in the forecast period include preventive strategies, patient-centered care, continuous monitoring, regulatory focus.

The increasing incidence of diabetes among pregnant women is anticipated to drive the expansion of the preeclampsia drug market in the future. Diabetes is a chronic metabolic disease characterized by elevated levels of blood glucose, and it can lead to detrimental effects on pregnancy, including preeclampsia. Metformin, a medication used in the management of preeclampsia, finds significant application among pregnant women at risk of developing this condition. As of December 2022, data from the National Library of Medicine, a US-based biomedical library and informatics center, reported a total of 20,865 cases of gestational diabetes mellitus (GDM) in 2022, signifying a 6.56% increase. Consequently, the upsurge in diabetes cases among pregnant women is expected to be a driving force behind the preeclampsia drug market's growth.

The increasing prevalence of lifestyle diseases is poised to stimulate the expansion of the preeclampsia drugs market. Lifestyle diseases, also known as non-communicable diseases (NCDs), encompass a group of health conditions primarily attributed to unhealthy lifestyle choices and behaviors. Preeclampsia drugs are instrumental in treating lifestyle-related ailments such as hypertension, obesity, and diabetes, all of which represent risk factors for preeclampsia. For example, in September 2022, as reported by the World Health Organization, a specialized agency of the United Nations based in Switzerland, non-communicable diseases (NCDs) or chronic diseases accounted for 74% of the 41 million global annual deaths. This included 17.9 million deaths due to cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths related to chronic respiratory diseases, and 2.0 million deaths associated with diabetes. Consequently, the burgeoning prevalence of lifestyle diseases is a key driver behind the growth of the preeclampsia drugs market.

Prominent companies operating in the preeclampsia medicine market are actively engaged in the development of advanced drug solutions to bolster their market presence. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical company, announced the FDA's approval of an investigational new drug (IND) application for CBP-4888, Comanche's unique siRNA therapy designed for preeclampsia treatment. CBP-4888 is a subcutaneously administered siRNA therapy that reduces the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. Excessive production of the sFLT1 protein in the placenta is the primary cause of preeclampsia, as it enters the mother's circulation. CBP-4888 has the potential to alleviate preeclampsia symptoms, including high blood pressure and organ damage, and may enable the safe extension of pregnancy.

In October 2022, Ginkgo Bioworks Inc., a US-based provider of advanced biological technology, acquired Zymergen Inc. for an undisclosed amount. This acquisition strengthens Ginkgo's platform by integrating essential automation and software capabilities while bringing a wealth of experience in diverse biological engineering. Zymergen Inc., a US-based biotechnology company specializing in preeclampsia treatments, complements Ginkgo's biotechnology portfolio.

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the preeclampsia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The preeclampsia drugs market consists of sales of labetalol, methyldopa and magnesium sulfate (prevent seizures). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preeclampsia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preeclampsia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preeclampsia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The preeclampsia drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Mild Preeclampsia; Severe Preeclampsia
• 2) By Treatment: Medication to Lower Hypertension (B.P); Corticosteroids; Anticonvulsants Medication
• 3) By Route of Administration: Oral; Parenteral; Other Route of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users
• Subsegments:
• 1) By Mild Preeclampsia: Blood Pressure Management; Proteinuria Monitoring; Lifestyle Modifications
• 2) By Severe Preeclampsia: Antihypertensive Medications; Magnesium Sulfate Therapy; Emergency Delivery Management
• Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Johnson & Johnson Co; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Preeclampsia Drugs Market Characteristics

3. Preeclampsia Drugs Market Trends And Strategies

4. Preeclampsia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Preeclampsia Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Preeclampsia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Preeclampsia Drugs Market Growth Rate Analysis
• 5.4. Global Preeclampsia Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Preeclampsia Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Preeclampsia Drugs Total Addressable Market (TAM)

6. Preeclampsia Drugs Market Segmentation

• 6.1. Global Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Preeclampsia
• Severe Preeclampsia
• 6.2. Global Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication to Lower Hypertension (B.P)
• Corticosteroids
• Anticonvulsants Medication
• 6.3. Global Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route of Administration
• 6.4. Global Preeclampsia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Preeclampsia Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Other End-Users
• 6.6. Global Preeclampsia Drugs Market, Sub-Segmentation Of Mild Preeclampsia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Pressure Management
• Proteinuria Monitoring
• Lifestyle Modifications
• 6.7. Global Preeclampsia Drugs Market, Sub-Segmentation Of Severe Preeclampsia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihypertensive Medications
• Magnesium Sulfate Therapy
• Emergency Delivery Management

7. Preeclampsia Drugs Market Regional And Country Analysis

• 7.1. Global Preeclampsia Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Preeclampsia Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Preeclampsia Drugs Market

• 8.1. Asia-Pacific Preeclampsia Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Preeclampsia Drugs Market

• 9.1. China Preeclampsia Drugs Market Overview
• 9.2. China Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Preeclampsia Drugs Market

• 10.1. India Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Preeclampsia Drugs Market

• 11.1. Japan Preeclampsia Drugs Market Overview
• 11.2. Japan Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Preeclampsia Drugs Market

• 12.1. Australia Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Preeclampsia Drugs Market

• 13.1. Indonesia Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Preeclampsia Drugs Market

• 14.1. South Korea Preeclampsia Drugs Market Overview
• 14.2. South Korea Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Preeclampsia Drugs Market

• 15.1. Western Europe Preeclampsia Drugs Market Overview
• 15.2. Western Europe Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Preeclampsia Drugs Market

• 16.1. UK Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Preeclampsia Drugs Market

• 17.1. Germany Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Preeclampsia Drugs Market

• 18.1. France Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Preeclampsia Drugs Market

• 19.1. Italy Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Preeclampsia Drugs Market

• 20.1. Spain Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Preeclampsia Drugs Market

• 21.1. Eastern Europe Preeclampsia Drugs Market Overview
• 21.2. Eastern Europe Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Preeclampsia Drugs Market

• 22.1. Russia Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Preeclampsia Drugs Market

• 23.1. North America Preeclampsia Drugs Market Overview
• 23.2. North America Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Preeclampsia Drugs Market

• 24.1. USA Preeclampsia Drugs Market Overview
• 24.2. USA Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Preeclampsia Drugs Market

• 25.1. Canada Preeclampsia Drugs Market Overview
• 25.2. Canada Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Preeclampsia Drugs Market

• 26.1. South America Preeclampsia Drugs Market Overview
• 26.2. South America Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Preeclampsia Drugs Market

• 27.1. Brazil Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Preeclampsia Drugs Market

• 28.1. Middle East Preeclampsia Drugs Market Overview
• 28.2. Middle East Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Preeclampsia Drugs Market

• 29.1. Africa Preeclampsia Drugs Market Overview
• 29.2. Africa Preeclampsia Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Preeclampsia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Preeclampsia Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Preeclampsia Drugs Market Competitive Landscape And Company Profiles

• 30.1. Preeclampsia Drugs Market Competitive Landscape
• 30.2. Preeclampsia Drugs Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Co Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Preeclampsia Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Celgene Corp
• 31.4. Thermo Fisher Scientific Inc.
• 31.5. AstraZeneca plc
• 31.6. Abbott Laboratories
• 31.7. GlaxoSmithKline PLC
• 31.8. Takeda Pharmaceuticals Company Limited
• 31.9. Eli Lilly and Company
• 31.10. Gilead Sciences Inc.
• 31.11. Amgen Inc.
• 31.12. Siemens Healthcare GmbH
• 31.13. Boehringer Ingelheim Group
• 31.14. Viatris Inc.
• 31.15. Baxter International Inc.

32. Global Preeclampsia Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Preeclampsia Drugs Market

34. Recent Developments In The Preeclampsia Drugs Market

35. Preeclampsia Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Preeclampsia Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Preeclampsia Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Preeclampsia Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer